Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma

Morie A Gertz; Francis K Buadi; Suzanne R Hayman; Martha Q Lacy; Angela Dispenzieri; David Dingli; Wilson I Gonsalves; Shaji Kumar; Prashant Kapoor; Taxiarchis Kourelis; William J Hogan

doi:10.1016/j.mayocp.2017.09.012

Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma

Mayo Clin Proc. 2018 Jan;93(1):56-58. doi: 10.1016/j.mayocp.2017.09.012.

Authors

Affiliations

¹ Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN. Electronic address: [email protected].
² Division of Hematolgy, Mayo Clinic, Rochester, MN.
³ Department of Medicine, Hematology/Oncology Division, Mayo Clinic, Rochester, MN.
⁴ Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN.

PMID: 29304921
DOI: 10.1016/j.mayocp.2017.09.012

Abstract

Systems have been put in place in the Mayo Clinic Stem Cell Transplantation program to reduce day-100 all-cause mortality. Currently our mortality has been reduced to 0.3%. Patients can undergo transplant as an outpatient, with a median hospital duration of 0 days and only 25% of patients requiring a hospital stay of 5 days or greater. Outpatient transplantation is safe and reduces patient-incurred costs.

Publication types

Case Reports

MeSH terms

Hematopoietic Stem Cell Transplantation / methods*
Hospitalization / statistics & numerical data
Humans
Length of Stay / statistics & numerical data
Male
Middle Aged
Minnesota
Multiple Myeloma / drug therapy*
Multiple Myeloma / surgery*
Outpatients / statistics & numerical data
Patient Safety / statistics & numerical data*
Transplantation, Autologous / methods*
Treatment Outcome